FDA approves gene therapy for Wiskott-Aldrich syndrome
Journal of Allergy and Clinical Immunology · 2026-06 · 157 (6) · 1256-1257
DOI: 10.1016/j.jaci.2026.04.003 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-06. Verfasst von Hans D Ochs. Beteiligte Einrichtung: Center for Immunity and Immunotherapies, Seattle Children's Research Institute, University of Washington, Seattle, Wash. Electronic address: Hans.och…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute, University of Washington, Seattle, Wash. Electronic address: Hans.ochs@seattlechildrens.org.
Zitieren
APA
Ochs, H. D. (2026). FDA approves gene therapy for Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology, 157(6), 1256-1257. https://doi.org/10.1016/j.jaci.2026.04.003
Vancouver
Ochs HD. FDA approves gene therapy for Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology. 2026;157(6):1256-1257. doi:10.1016/j.jaci.2026.04.003
BibTeX
@article{Ochs2026,
author = {Ochs, Hans D},
title = {FDA approves gene therapy for Wiskott-Aldrich syndrome},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {157},
number = {6},
pages = {1256--1257},
doi = {10.1016/j.jaci.2026.04.003}
}
EUVIMED